povetacicept
povetacicept: 6 clinical trials tracked.
povetacicept evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about povetacicept, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Clinical Trial Registry Records (6)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis
Primary endpoint: Percent change in Total Immunoglobulin G (IgG)
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Primary endpoint: Proportion of Participants with Complete Clinical Remission Definition 1 (CR1)
A Phase 1, Open-label, Randomized, 2-part Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations in Healthy Subjects
Primary endpoint: Area Under the Concentration Versus Time Curve From the Time of Dosing to 28 Days (AUC0-28d) of Free Povetacicept
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER)
Primary endpoint: Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (uPCR) at Week 36
Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)
Primary endpoint: Safety and Tolerability as Assessed by Adverse events (AEs) and Serious adverse events (SAEs)
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)
Primary endpoint: Part A: Safety as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)